{"prompt": "['Protocol VX18-445-109, Version 1.0', 'Page 46 of 60', 'TEAEs', 'Related TEAEs', 'TEAEs by maximum severity', 'Grade 3/4 TEAEs', 'Serious TEAEs', 'Related serious TEAEs', 'AE of special interest (details will be described in SAP)', 'TEAEs leading to treatment discontinuation', 'TEAEs leading to treatment interruption', 'Summaries will be presented by MedDRA SOC and PT using frequency counts and percentages', '(i.e., number and percentage of subjects with an event). When summarizing the number and', 'percentage of subjects with an event, subjects with multiple occurrences of the same AE or a', 'continuing AE will be counted once, only the maximum severity level will be presented in the', 'severity summaries, and the strongest relationship level in the relationship summaries.', 'Listings containing individual subject level AE data will be provided separately for:', 'Serious TEAEs', 'TEAEs leading to treatment discontinuation', 'TEAEs leading to treatment interruption', 'TEAEs leading to death', 'In addition, all AEs, including pre- and post-treatment AEs, will be presented in individual', 'subject data listings.', '12.3.4.2', 'Clinical Laboratory Assessments', 'For the treatment-emergent laboratory measurements, the observed values and change from', 'baseline values of the continuous hematology, serum chemistry, and coagulation results will be', 'summarized in SI units by treatment group at each visit.', 'The number and percentage of subjects with at least 1 threshold analysis event during the', 'TE Period will be summarized by treatment group. The threshold analysis criterion shift from', 'baseline will also be summarized for select laboratory parameters. The threshold analysis criteria', 'and the parameter selection criteria will be provided in the SAP.', 'Results of urinalysis and pregnancy tests will be listed in individual subject data listings only. In', 'addition, a listing containing individual subject hematology, chemistry, and coagulation values', 'will be provided. This listing will include data from scheduled and unscheduled visits.', '12.3.4.3', 'Electrocardiogram', 'For the treatment-emergent ECG measurements, a summary of observed values and change from', 'baseline values will be provided by treatment group, at each visit and time point, as applicable,', 'for the following ECG interval measurements (in msec): RR, PR, QT, and QT corrected for heart', 'rate (QTcF), QRS duration, and HR (beats per minute).', 'Vertex Pharmaceuticals Incorporated']['Protocol VX18-445-109, Version 1.0', 'Page 47 of 60', 'The number and percentage of subjects with at least 1 threshold analysis event during the', 'TE Period will be summarized by treatment group. The threshold analysis criteria will be', 'provided in the SAP.', 'Additional ECG analyses may be described in the SAP.', '12.3.4.4', 'Vital Signs', 'For the treatment-emergent vital signs measurements, the observed values and change from', 'baseline values will be summarized by treatment group at each visit. The following vital signs', 'parameters will be summarized: systolic and diastolic blood pressure (mm Hg), body', 'temperature (\u00b0C), pulse rate (beats per minute), and respiratory rate (breaths per minute).', 'The number and percentage of subjects with at least 1 threshold analysis event during the', 'TE Period will be summarized by treatment group. The threshold analysis criteria will be', 'provided in the SAP.', 'Additional vital signs analyses may be described in the SAP.', '12.3.4.5', 'Pulse Oximetry', 'For the treatment-emergent pulse oximetry measurements, a summary of observed values and', 'change from baseline values will be provided by treatment group, at each visit for the percent of', 'oxygen saturation by pulse oximetry.', 'The number and percentage of subjects with shift changes from baseline (normal/missing and', 'low according to the reference range) to the lowest percent of oxygen saturation during the', 'TE Period will be summarized by treatment group.', '12.3.4.6', 'Physical Examination', 'PE findings will be presented in an individual subject data listing only.', '12.3.5', 'Interim and IDMC Analyses', '12.3.5.1', 'Interim Analysis', 'An IA may be performed when approximately 70% subjects complete the Week 24 Visit. To', \"control the family-wise type 1 error rate, O'Brien-Fleming20 group sequential boundaries will be\", 'applied. Specifically, if the number of subjects included in the IA is 108, the null hypotheses will', 'be tested at a 2-sided significance level of 0.014 at the IA and 0.046 at final analysis. The actual', 'boundaries at the IA and final analysis will be calculated based on the number of actual subjects', 'included in the IA.', 'The Vertex Biometrics team will assign an internal biostatistician independent of the study team', 'or a designated independent third-party vendor to perform the IA. The assigned independent', 'statistician/vendor will not be involved in or influence the conduct of the study.', '12.3.5.2', 'IDMC Analysis', 'Not applicable.', 'Vertex Pharmaceuticals Incorporated']\n\n###\n\n", "completion": "END"}